Department of Psychosomatic Medicine, University Medical Center Rostock, Rostock, Germany;
Deutsches Zentrum für Neurodegenerative Erkrankungen, Rostock/Greifswald, Rostock, Germany.
J Nucl Med. 2022 Jul;63(7):981-985. doi: 10.2967/jnumed.121.262239. Epub 2022 Feb 10.
Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.
阿尔茨海默病(AD)是 60 岁及以上人群中最常见的痴呆症病因。本白皮书总结了 AD 的诊断、治疗、护理和预防的当前标准。脑脊液和正电子发射断层扫描(PET)测量脑淀粉样蛋白和tau 病可在痴呆(前驱期)之前诊断 AD,并为旨在减缓 AD 病程的治疗提供终点。已批准的药物治疗可增强胆碱能通路并适度减轻谷氨酸能传递过度,从而稳定认知功能。疾病修饰性实验药物可减轻或清除脑淀粉样蛋白,但到目前为止,临床效果有限。非药物干预和健康的生活方式(饮食、社会情感包容、认知刺激、体育锻炼等)提供了一些有益的效果。预防的主要目标是针对可改变的痴呆风险因素,如不健康的生活方式、心血管代谢和睡眠-觉醒周期异常以及精神障碍。未来的一个主要挑战是在现实世界中对这些可改变的风险因素进行远程监测。